Collaboration aims to increase the availability of engineered T cell therapies by speeding up development of automation technologies
Light-activated repair system discovered in algae may prove useful in excising interrupting sequences from proteins
Catalent says the $200 million it will spend over three years to expand drug substance manufacturing capacity and drug product fill/finish capacity in Bloomington, IN, and Madison, WI, reflects a commitment to expand further...
Lack of pathogenicity and other advantages over Escherichia coli make Bacillus subtilis an attractive host expression system, says GenScript, especially if secretory capacity is enhanced.
New GE Healthcare Life Sciences Manufacturing Facility will include 7,360 square meters in the new Signy Park for the manufacture of single use kits for the Sepax and Sefia cell processing systems. Company officials say the facility will meet global regulatory requirements and is expected to be fully operational in 2022.
Please wait while you are redirected to the right page...